91΄σΙρ

91΄σΙρ College of Wisconsin
91΄σΙρ College of Wisconsin 91΄σΙρ College of Wisconsin
GettyImages-609179959-hero
Hematology and Oncology

Radhakrishnan Laboratory

The research focus of the Radhakrishnan lab is to advance the field of cellular immunotherapy and is based on two divergent yet complimentary themes:

1) Development of CAR T cells targeting novel antigens for both solid and hematological cancers. The lab uses antibody phage display library and high throughput downstream assays to identify binding antibodies and functional CAR T cells. Using this platform, during his post-doctoral training at the University of Utah, Dr. Radhakrishnan has developed the first human CD229 antibody and CAR T cells and shown efficacy in multiple myeloma and B cell neoplasms.

2) Overcoming immunosuppressive tumor microenvironment to enhance CAR T cell therapy. The Radhakrishnan lab employs a multimodal approach to activate tumor macrophages using CAR T cells, thus enhancing their tumoricidal effect. In this regard the lab focuses on targeting the “do not eat me signal” CD47 and CD24 to enhance CAR T cell or tumor infiltrating lymphocytes in both solid and hematological cancers.

Radhakrishnan Laboratory

91΄σΙρ the PI

Sabari Radhakrishnan, MDSabarinath Radhakrishnan, MD, is an Assistant Professor in the Division of Hematology & Oncology at the 91΄σΙρ College of Wisconsin. He obtained his medical degree (MBBS) and post graduate degree (MD) from Trivandrum 91΄σΙρ College, Kerala, India and further completed Internal Medicine residency at LSU Shreveport and Hematology/Oncology fellowship at the University of Utah. His initial research focus was on graft versus host disease and trained under the mentorship of Gerhard Hildebrandt MD at LSU Shreveport. During his fellowship at the University of Utah, under the guidance of Tim Luetkens, MD and Djordje Atanackovic, MD, he developed a high throughput CAR T cell discovery platform using phage display technology and successfully generated the first CD229 targeting CAR T cells.

Dr. Radhakrishnan joined 91΄σΙρin 2021 and attends to the bone marrow transplant and cellular therapy service at Froedtert Hospital and his lab is focused on developing CAR T cells against novel targets and overcoming CAR T cell resistance.

Current Members

headshot

Maday Galeana Figueroa

Research Associate I

headshot

Kishan Nyati, PhD

Postdoctoral Fellow

headshot

Tarang Sharma, PhD

Postdoctoral Fellow

Recent Publications

  • (Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C.) Haematologica. 2024 Mar 01;109(3):906-914 PMID: 37646658 PMCID: PMC10905074 SCOPUS ID: 2-s2.0-85178101970 08/30/2023

  • (Vander Mause ER, Baker JM, Dietze KA, Radhakrishnan SV, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T.) Sci Transl Med. 2023 Jul 19;15(705):eadd7900 PMID: 37467316 SCOPUS ID: 2-s2.0-85165317486 07/19/2023

  • (Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C.) Am J Hematol. 2022 Dec;97(12):E451-E453 PMID: 36097868 SCOPUS ID: 2-s2.0-85139019826 09/14/2022

  • (Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C.) Am J Hematol. 2022 Jul;97(7):E276-E280 PMID: 35472167 PMCID: PMC10476149 SCOPUS ID: 2-s2.0-85129190892 04/27/2022

  • (Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P.) Blood Adv. 2022 Apr 26;6(8):2466-2470 PMID: 34933344 PMCID: PMC9043928 SCOPUS ID: 2-s2.0-85129331026 12/22/2021

  • (Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T.) Leukemia. July 2022;36(7):1943-1946 SCOPUS ID: 2-s2.0-85129213162 07/01/2022

  • (Palaniyandi S, Kumari R, Venniyil Radhakrishnan S, Strattan E, Hakim N, Munker R, Kesler MV, Hildebrandt GC.) Transplantation. 2020 Dec;104(12):2507-2515 PMID: 32639407 PMCID: PMC8139022 SCOPUS ID: 2-s2.0-85096509107 07/09/2020

  • (Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D.) Nat Commun. 2020 Feb 07;11(1):798 PMID: 32034142 PMCID: PMC7005855 SCOPUS ID: 2-s2.0-85079080842 02/09/2020

  • (Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T.) Leukemia. 2020 Jan;34(1):317-321 PMID: 31409922 SCOPUS ID: 2-s2.0-85070798814 08/15/2019

  • (Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G.) Cell Transplant. 2019 Dec;28(12):1624-1631 PMID: 31619057 PMCID: PMC6923548 SCOPUS ID: 2-s2.0-85076876281 10/18/2019

  • (Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D.) Clin Immunol. 2019 Jul;204:69-73 PMID: 30326256 SCOPUS ID: 2-s2.0-85055712528 10/17/2018

  • (Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D.) Oncoimmunology. 2017;6(5):e1308618 PMID: 28638731 PMCID: PMC5468000 SCOPUS ID: 2-s2.0-85019019970 06/24/2017

Publications of from the